Sarecycline

Summary

Sarecycline (CHEMBL2364632) is an approved small molecule (ATC J01AA14); indicated across 3 conditions including bacterial infectious disease and acne.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01AA14
• Indications: 3 conditions
• Clinical trials: 8
• Chemistry: 487.5 Da · C24H29N3O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2364632
Name	Sarecycline
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	54681908
ATC	J01AA14
Molecular formula	C24H29N3O8
Molecular weight	487.5
InChIKey	AYUMVPHUMFKFPJ-SBAJWEJLSA-N

SMILES: CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)CN(C)OC

IUPAC name: (4S,4aS,5aR,12aR)-4-(dimethylamino)-1,10,11,12a-tetrahydroxy-7-[[methoxy(methyl)amino]methyl]-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide

Also known as: P-005672, P005672, Sareciclina, Sarecycline, SARECYCLINE, SARECYCLINE HYDROCHLORIDE

Parent form; salt/anhydrous children: CHEMBL2364633

Patent coverage: 235 distinct patent families (494 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 454 (92%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
acne	3	MONDO:0011438	EFO:0003894

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE3	3
PHASE4	2
Not specified	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07544251	PHASE4	RECRUITING	Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.
NCT04555525	PHASE4	COMPLETED	A Pilot Study on the Use of Seysara for Rosacea
NCT02320149	PHASE3	COMPLETED	Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
NCT02322866	PHASE3	COMPLETED	Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
NCT02413346	PHASE3	COMPLETED	A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
NCT05836753	PHASE2	UNKNOWN	Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy
NCT04820673	Not specified	COMPLETED	Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)
NCT05010538	Not specified	COMPLETED	Sarecycline Truncal Acne Safety and Efficacy Response

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).